13th Nov 2026 12:18
(Alliance News) - AstraZeneca PLC on Friday said the EU's Committee for Medicinal Products for Human Use has recommended Baxfendy, or baxdrostat, for approval as an arterial hypertension treatment.
The recommendation, from the European Medicines Agency's CHMP, covers adults with arterial hypertension insufficiently controlled with at least two antihypertensive medicinal products.
AstraZeneca said that if approved in the EU, Baxfendy will be the region's first and only aldosterone synthase inhibitor.
The Cambridge, England-based pharmaceuticals company said the CHMP based its opinion on results from the "pivotal" BaxHTN and Bax24 phase 3 studies.
In the trials, Baxfendy "demonstrated statistically significant and clinically meaningful reductions in seated systolic blood pressure (SBP) in patients with uncontrolled or resistant hypertension, and 24-hour average ambulatory SBP in patients with resistant hypertension," Astra said.
"Hypertension is often called the 'silent killer' and is a leading risk factor for heart attack, stroke and dementia," commented Ruud Dobber, president of Astra's BioPharmaceuticals Business Unit. "This positive CHMP opinion for Baxfendy marks a significant step toward bringing this potential first-in-class innovation to patients in Europe.
"This novel medicine reflects the strength of our pipeline across interconnected cardiovascular, renal and metabolic diseases as we deliver on our 2030 ambition to bring 20 new medicines to the world."
AstraZeneca shares were 0.1% higher at 13,940.00 pence on Friday afternoon in London.
By Emma Curzon, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca